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Gastrointestinal (GI) side-effects of chemotherapy are a debilitating and often overlooked
clinical hurdle in cancer management. Chemotherapy-induced constipation (CIC) and
Diarrhea (CID) present a constant challenge in the efficient and tolerable treatment
of cancer and are amongst the primary contributors to dose reductions, delays and
cessation of treatment. Although prevalence of CIC is hard to estimate, it is believed to
affect approximately 16% of cancer patients, whilst incidence of CID has been estimated
to be as high as 80%. Despite this, the underlying mechanisms of both CID and CIC
remain unclear, but are believed to result from a combination of intersecting mechanisms
including inflammation, secretory dysfunctions, GI dysmotility and alterations in GI
innervation. Current treatments for CIC and CID aim to reduce the severity of symptoms
rather than combating the pathophysiological mechanisms of dysfunction, and often
result in worsening of already chronic GI symptoms or trigger the onset of a plethora
of other side-effects including respiratory depression, uneven heartbeat, seizures, and
neurotoxicity. Emerging treatments including those targeting the enteric nervous system
present promising avenues to alleviate CID and CIC. Identification of potential targets for
novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clinical
outcomes and quality of life amongst cancer sufferers.
Keywords: chemotherapy, chemotherapy-induced constipation, chemotherapy-induced diarrhea, pathophy-
siology, treatments
INTRODUCTION
Cancer is a leading cause of death worldwide (Jemal et al., 2011; Torre et al., 2015) with
approximately 14.1 million new cancer cases and 8.2 million cancer deaths in 2012 alone (Ferlay
et al., 2015). Although advances in modern medicine have improved scanning and cancer detection
techniques, the burden for global health of cancer is expected to intensify in decades to come
particularly in low and middle income families and economically developed countries (Jemal et al.,
2010a,b). Population aging and growth coupled with the adoption of high risk lifestyle choices
Abbreviations: CIC, chemotherapy-induced constipation; CID, chemotherapy-induced diarrhea; ENS, enteric nervous
system; GI, gastrointestinal.
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such as smoking, physical inactivity, and westernization of diets
have been identified as underlying factors contributing to the
increasing incidence of cancer worldwide (Jemal et al., 2011). It
is now anticipated that by 2025 more than 20 million people will
be affected by cancer (Ferlay et al., 2015).
Most cancer patients receive curative or palliative
chemotherapeutic intervention throughout the course of
treatment (Louvet et al., 2002; Benson et al., 2004b; Kaufmann
et al., 2006; Wagner et al., 2006; Goffin et al., 2010; Okines et al.,
2010). Although chemotherapy has greatly improved overall
survival in many types of cancer, cytotoxic side-effects are a
significant hurdle greatly impeding the clinical application of
otherwise beneficial therapies (Xue et al., 2011; Iwamoto, 2013).
GI side-effects such as nausea, vomiting, ulceration, bloating,
constipation and, in particular, diarrhea are major obstacles
causing delays, adjustments, and discontinuation of treatment
whilst greatly impacting quality of life in many cancer patients
(Benson et al., 2004a; Stringer et al., 2007, 2009d; Denlinger
and Barsevick, 2009; Peterson et al., 2011). Although specific
chemotherapeutic agents have been correlated with heightened
incidence of GI side-effects (Table 1), incidences as high as
40% in patients receiving standard dose chemotherapy and
100% in patients receiving high dose chemotherapy have been
reported (McQuade et al., 2014). Furthermore, the incidence
of chronic post-treatment constipation and diarrhea amongst
cancer survivors has been estimated to be as high as 49% with
episodes persisting up to 10 years after the cessation of treatment
(Schneider et al., 2007; Denlinger and Barsevick, 2009; Kim et al.,
2012). The underlying mechanisms of CIC and diarrhea (CID)
remain unclear. Although mucositis presenting as inflammation
and ulceration of the intestinal epithelium is a significant
contributing factor, the pathophysiology of CID and CIC is likely
to be complex, involving several overlapping inflammatory,
secretory and neural mechanisms.
CHEMOTHERAPY-INDUCED DIARRHEA
Diarrhea is a frequently under-recognized clinical issue that
significantly affects morbidity and mortality of cancer patients
worldwide (Maroun et al., 2007). Prevalence and severity
of CID vary greatly depending on chemotherapeutic regime
administration and dosage. A direct correlation between
cumulative dose and severity of CID has been recognized, with
high dose regimens associated with heightened incidence of
CID (Verstappen et al., 2003). Certain regimens, especially those
containing 5-fluorouracil and irinotecan are associated with
rates of CID of up to 80% (Benson et al., 2004a; Richardson
and Dobish, 2007) with one third of patients experiencing
severe (grade 3 or 4) diarrhea (Table 2) (Maroun et al.,
2007).
Chemotherapy-induced diarrhea severely interferes with
anti-cancer treatment, resulting in treatment alterations in
approximately 60% of patients, dose reductions in 22%
of patients, dose delays in 28% of patients and complete
termination of treatment in 15% of patients (Arbuckle et al.,
2000; Dranitsaris et al., 2005). Moreover, CID has been
reported to last as long as 10 years post-treatment (Denlinger
and Barsevick, 2009). Persistent and severe chemotherapy-
associated Diarrhea is correlated with significant malnutrition
and dehydration resulting in concomitant weight loss (cachexia),
fatigue, renal failure, hemorrhoids, and perianal skin breakdown
(Mitchell, 2006; Shafi and Bresalier, 2010). CID related
dehydration is linked to early death rates in roughly 5%
of patients undergoing anti-cancer treatment (Rothenberg
et al., 2001). Further to this, chemotherapeutic administration
may also prompt severe intestinal inflammation, bowel wall
thickening and ulceration (Kuebler et al., 2007) contributing to
clinical disruptions with potentially life-threatening ramifications
(Rothenberg et al., 2001; Benson et al., 2004a; Stein et al.,
2010).
For over 30% of CID sufferers it interferes with their daily
activities (Stein et al., 2010), with detrimental effects on the
mental and social health of cancer survivors. Persistent and
uncontrollable CID has been linked to anxiety, depression, social
isolation, and low self-esteem (Viele, 2003), emphasizing the
importance of both elucidating the underlying mechanisms of
CID and improving treatment efficacy (Carelle et al., 2002).
Pathophysiology of
Chemotherapy-Induced Diarrhea
Although several chemotherapy regimens have been associated
with Diarrhea to varying degrees (Table 1), most basic research
into the mechanisms underlying CID has focused on irinotecan
and its active metabolite SN38 (Gibson and Keefe, 2006). As
diarrhea is a well-recognized side-effect of irinotecan treatment,
the histological changes that occur throughout the GI tract in
response to irinotecan administration have been examined in
several animal studies (Araki et al., 1993; Ikuno et al., 1995;
Takasuna et al., 1996; Gibson et al., 2003). Pronounced crypt
ablation, villus blunting and epithelial atrophy in the small and
large intestines have been reported (Logan et al., 2008), resulting
in mucosal damage and degeneration being a major theme
throughout the literature surrounding CID. Although patients
do not routinely have imaging or endoscopy to diagnose the
chemotherapy-induced mucosal inflammation (Touchefeu et al.,
2014), CID is still largely believed to be a form, or by-product, of
GI mucositis. Mucositis is defined as mucosal injury presenting as
inflammation and ulceration, resulting in alterations of intestinal
microflora and GI secretion (Stringer, 2009; Stringer et al.,
2009a,b). The basic pathophysiology of mucositis can be broken
into 5 sequential phases: (i) initiation; (ii) up-regulation; (iii)
signaling and amplification; (iv) ulceration and inflammation;
and (v) healing (Sonis et al., 2004; Lee et al., 2014).
Initiation of mucositis is believed to result from direct
or indirect effects of cytotoxic chemotherapeutics on the
rapidly dividing epithelial cells in GI tract, triggering apoptosis.
This leads to reductions in crypt length and villus area,
coupled with activation of nuclear factor-kappa B (NFκB)
and subsequent up-regulation of pro-inflammatory cytokines
including interleukin 1 (Lawrence, 2009), which contribute to
ulceration and inflammation in the mucosal epithelium (Gibson
et al., 2003; Stringer et al., 2007, 2008, 2009a,d; Logan et al.,
2008). Intestinal microbiota is known to play an integral role in
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intestinal homeostasis and are now believed to play a key role in
the development of mucositis (van Vliet et al., 2010; Touchefeu
et al., 2014). Recent studies have revealed that chemotherapeutic
administration has effects on intestinal microbial composition
(Stringer et al., 2009a,b), and fecal microbiota (Touchefeu et al.,
2014).
Much of the research investigating the effects of
chemotherapeutic administration on microbiota has focused
primarily on topoisomerase I inhibitor, irinotecan, due to
the involvement of microbiota in its metabolism (Stringer,
2013). Upon metabolism in the liver, irinotecan is converted
to its active metabolite SN-38 by enzyme carboxylesterase,
before being deactivated through glucuronidation by uridine
diphosphate glucuronosyltransferase 1A1 (UGT1A1) to
form SN38 glucuronide (SN38-G). However, SN38G may be
reactivated to SN38 in the presence of enzyme β-glucuronidase,
which may be produced by the intestinal microbiome. Several
studies have shown a shift in commensal bacteria, in particular
Bifidobacterium spp. toward Salmonella spp. and Escherichia
coli following irinotecan administration (Stringer et al., 2009b).
Of the β-glucuronidase-producing bacteria, Bacteroides spp.
has been shown to decrease following irinotecan treatment,
concurrently Staphylococcus spp., Clostridium spp. and E. coli
have been found to be increased, whilst presence of beneficial
bacteria, Lactobacillus spp. and Bifidobacterium spp. was
decreased following irinotecan treatment (Stringer et al., 2007).
When given in combination with antimetabolite 5-fluorouracil,
both Clostridium cluster XI and Enterobacteriaceae presence was
found to be increased, whilst treatment with 5-fluorouracil alone
has also been found to increase the presence of Clostridium spp.
and Staphylococcus spp. at 24 h post-treatment (Stringer et al.,
2009c).
These changes in microbiota are believed to play an
important role not only in maintaining intestinal homeostasis
and integrity but in the modulation of inflammatory responses
through interaction with Toll-like receptors and the nucleotide
TABLE 1 | Gastrointestinal side-effects of chemotherapy.
Mechanisms Chemotherapeutic
agents
Cancer type GI side-effects
Alkylating Agents Cisplatin Lung, Breast, Stomach,
Colorectal, Liver
Nausea, Vomiting, Diarrhea, Constipation (Ilson et al., 1999;
Ardizzoni et al., 2007)
Cyclophosphamide Breast Nausea, Vomiting, Abdominal Pain, Diarrhea (Fraiser et al., 1991;
Boussios et al., 2012)
Oxaliplatin Colorectal, Breast,
Stomach
Nausea, Vomiting, Diarrhea, Constipation (Extra et al., 1990; Kim
et al., 2003)
Antimetabolites 5-Fluorouracil Breast, Colorectal,
Stomach, Liver
Nausea, Vomiting, Abdominal Pain, Diarrhea (Douillard et al., 2010;
Boussios et al., 2012)
Capecitabine Colorectal, Breast,
Stomach
Nausea, Vomiting, Diarrhea (Walko and Lindley, 2005; Stathopoulos
et al., 2007; Boussios et al., 2012)
Gemcitabine Lung, Breast Nausea, Vomiting, Abdominal Pain, Constipation, Diarrhea (Wolff
et al., 2001; Mutch et al., 2007; Boussios et al., 2012)
Methotrexate Breast Nausea, Vomiting, Abdominal Pain, Diarrhea (Boussios et al., 2012)
Anthracycline Doxorubicin Breast, Lung, Liver Nausea, Vomiting, Abdominal pain, GI Ulceration, Diarrhea (Boussios
et al., 2012; Tacar et al., 2013)
Immunomodulating agent Thalidomide Myeloma, Kidney Nausea, Vomiting, Diarrhea, Constipation (Smith et al., 2008)
Mitotic inhibitors Cabazitaxel Prostate Nausea, Vomiting, Abdominal pain, Diarrhea (Nightingale and Ryu,
2012; Dieras et al., 2013)
Docetaxel Prostate, Breast, Lung,
Stomach
Nausea, Vomiting, Diarrhea (Boussios et al., 2012)
Paclitaxel Lung, Stomach,
Prostate, Breast
Nausea, Vomiting, Diarrhea (Boussios et al., 2012)
Vincristine Breast, Lung Constipation, Abdominal Pain (Holland et al., 1973)
Topoisomerase inhibitor Irinotecan Colorectal, Breast,
Stomach, Lung
Nausea, Vomiting, Acute and Delayed Diarrhea (Hecht, 1998)
TABLE 2 | Common toxicity criteria for diarrhea and constipation grading (adapted from the National Cancer Institute).
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Diarrhea Increase of <4 stools per day
over baseline.
Increase of 4–6 stools per day over
baseline.
Increase of >7 stools per day
over baseline. Incontinence.
Hospitalization.
Life threatening
consequences. Urgent
intervention indicated.
Death
Constipation Occasional or intermittent
symptoms; occasional use of
stool softeners, laxatives,
dietary modification, or enema.
Persistent symptoms with regular use
of laxatives or enemas indicated.
Symptoms interfering with
activities of daily living;
obstipation with manual
evacuation indicated
Life-threatening
consequences (e.g.,
obstruction, toxic
megacolon).
Death
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oligomerization domain receptors that activate NFκB (van Vliet
et al., 2010). In the healing phase, proliferation and differentiation
of the GI epithelium return approximately 2 weeks post-
chemotherapy (Sonis et al., 2004; Lee et al., 2014), but functional
changes persist after recovery of morphological changes (Keefe
et al., 2000; Rubenstein et al., 2004). The pathophysiology
underlying these persistent changes in GI functions includes
several overlapping secretory, osmotic, inflammatory, and
neurogenic mechanisms (McQuade et al., 2014).
Disruption to water and electrolyte balance within the GI
tract is a key component in the pathophysiology of all types of
diarrhea. Direct mucosal damage has been suggested as a major
contributor to malabsorption and hypersecretion associated with
CID (Richardson and Dobish, 2007; Stringer et al., 2007, 2009b;
Stein et al., 2010). Studies using animal models of CID have
demonstrated increased apoptosis in the crypts of both the
jejunum and colon, resulting in metaplasia of goblet cells and
excessive mucous secretion (Ikuno et al., 1995; Gibson et al.,
2003). Hyperplasia of the rapidly dividing crypt cells in the
epithelium of the gut probably results in heightened proportions
of immature secretory cells, leading to increased secretion and
decreased absorptive capacity of the villi, thereby contributing to
the onset of diarrhea (Castro-Rodríguez et al., 1997). Retention of
non-absorbable compounds within the lumen triggers an osmotic
shift of water into the lumen (Castro-Rodríguez et al., 1997;
Richardson and Dobish, 2007; Stringer et al., 2007). This reduced
absorptive capacity and increased secretion in the small intestines
results in increased fluid and solutes in the intestinal lumen and
overwhelms the absorptive capacity of the colon resulting in
diarrhea (Gibson and Keefe, 2006).
Secondary to mucosal damage, CID has been associated
with mucosal inflammation throughout the GI tract (Logan
et al., 2008). Increased expression of cyclooxygenase (COX)-2,
associated with increased release of prostaglandin E2 (PGE2), is
seen in rat colon following irinotecan administration (Yang et al.,
2005). PGE2 stimulates colonic secretion and hyperperistalsis
of the gut, whilst inhibiting sodium, potassium and adenosine
triphosphatase, and triggering excessive chloride secretion, all
of which further contribute to the onset of diarrhea (Kase
et al., 1997a,b; Leahy et al., 2002; Yang et al., 2005). Further,
irinotecan stimulates the production of thromboxane A2, a
potent physiological stimulant of chloride and water secretion
in the colon (Sakai et al., 1997; Suzuki et al., 2000) as well as
tumor necrosis factor- α (TNF-α) a pro-inflammatory cytokine
and a primary mediator of immune regulation associated with
CID (Yang et al., 2005).
Chemotherapy can induce damage to the ENS (Vera et al.,
2011; Wafai et al., 2013) which may also underlie GI secretory
disturbances involved in pathophysiology of CID. Innervation of
the GI tract is primarily from the ENS, sometimes referred to as
“the second brain” due to its ability to function autonomously
of the central nervous system (Phillips and Powley, 2007). The
ENS is comprised of ganglia, primary interganglionic fiber tracts
as well as secondary and tertiary fibers which project to many of
the effector systems of the gut including muscle cells, glands, and
blood vessels (Hansen, 2003). The ENS is divided into two major
ganglionated plexi, the myenteric (Auerbach’s), and submucosal
(Meissner’s), which are responsible for controlling gut functions
including motility, secretion, absorption and vascular tone.
Enteric neuropathy has been linked to a variety of GI pathologies,
in part due to its regulation of intestinal epithelial function and
colonic motility (De Giorgio et al., 2000, 2004; De Giorgio and
Camilleri, 2004; Chandrasekharan et al., 2011; Furness, 2012).
However, effects of chemotherapeutics on enteric neurons and
GI dysfunction have been largely overlooked until recently. It
has been shown that chronic treatment with cisplatin results in
myenteric neuronal loss, increase in amplitude of the neurally
induced contractions of the gastric fundus strips in mice and
occasional diarrhea (Pini et al., 2016). Thus enteric neuropathy
may be an underlying cause of chemotherapy-induced GI
dysmotility.
Movement of fluid between the lumen of the intestine and
the body fluid compartments is a complex and tightly regulated
process involving neural, endocrine, paracrine, and autocrine
systems that act via the enteric neurons within the submucosal
plexus (Lundgren et al., 2000; Johnson et al., 2012). Situated
superficially to the mucosa, the submucosal plexus lies between
the circular muscle and muscularis mucosa layer of the mucosa
and derives innervation from neurons in the myenteric plexus
as well as direct innervation from branches of the sympathetic
and parasympathetic nervous systems. The submucosal plexus
innervates the mucosal epithelium and submucosal arterioles to
control and maintain water and electrolyte balance, secretion
and vascular tone (Furness, 2012). Fluid is absorbed from the
lumen containing nutrients via ion-coupled transporters and
returned through secretomotor reflexes. Through activation of
secretomotor neurons, water and electrolytes are moved from
the interstitium of the lamina propria to the lumen, drawn from
both the circulation and the absorbed fluids. Neural control
of secretion and absorption of water and electrolytes occurs
on multiple interacting levels. While there are secretomotor
circuits confined to the submucosal plexus, they can be directly
controlled by circuitry within the myenteric plexus. Despite the
important role of the ENS in controlling secretory function, very
little research has been undertaken to elucidate the relationship
between the ENS and CID. Enteric neuropathy and/or neuronal
dysfunction may be a contributing factor in chemotherapy-
induced secretory dysfunction.
Current Treatments for
Chemotherapy-Induced Diarrhea
Chemotherapy-induced diarrhea may be classified as
uncomplicated (grade 1–2 with no complications) or complicated
(grade 3–4 with one or more complicating signs or symptoms),
early onset (<24 h after administration) or late onset (>24 h after
administration) and may be categorized as persistent (present for
>4 weeks) or non-persistent (present for <4 weeks) according
to the National Cancer Institute’s Common Terminology
Criteria for Adverse Effects grading system (Stein et al., 2010).
Although uncomplicated CID may be managed by modification
of the diet and administration of standard anti-diarrheal
drugs such as loperamide, octreotide and tincture of opium,
complicated diarrhea requires aggressive high dose anti-diarrheal
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administration and hospitalization (McQuade et al., 2014). The
recommendations on the management of CID were published
in 1998 and updated in 2004 (Wadler et al., 1998; Benson et al.,
2004a), providing guidelines for evaluation and management
of CID. These guidelines have not been updated since 2004.
Currently the only drugs recommended in the updated treatment
guidelines are opioid derivatives such as loperamide and
deodorized tincture of opium (DTO), and octreotide.
Loperamide
Loperamide is a non-analgesic agonist that acts at µ-opioid
receptors at the level of the myenteric plexus to decrease intestinal
motility (Regnard et al., 2011). High dose loperamide alleviates
diarrhea associated with chemotherapeutic administration (Stein
et al., 2010). However, its use leads to a range of side-effects
including severe constipation, abdominal pain, dizziness, rashes
as well as worsening of already present bloating, nausea and
vomiting (Lenfers et al., 1999; Stein et al., 2010). High dose
loperamide is reported to increase incidents of paralytic ileus,
in association with abdominal distension (Sharma et al., 2005;
Richardson and Dobish, 2007). Despite these severe side-effects,
loperamide remains the standard first line therapy for CID.
Octreotide
Octreotide is a synthetic somatostatin analog that promotes
absorption by inhibiting specific gut hormones to increase
intestinal transit time (Högenauer et al., 2002; Mitchell,
2006) as well as hyperpolarizing enteric secretomotor neurons
(Högenauer et al., 2002). Octreotide is administered to treat both
complicated diarrhea and loperamide-refractory diarrhea and is
generally reserved as a second line treatment for patients who are
unresponsive to loperamide after 48 h, despite loperamide dose
escalation (Regnard et al., 2011). Although octreotide decreases
CID effectively, severe side-effects including slow and/or uneven
heartbeat, severe constipation, stomach pain, enlarged thyroid,
vomiting, nausea, headache and dizziness occur in over 10% of
patients (Bhattacharya et al., 2008).
Deodorised Tincture of Opium
Deodorized tincture of opium (DTO) is another widely used
antidiarrheal agent, despite the absence of literature to support
its use in CID treatment (Stein et al., 2010). Similar to
loperamide, DTO activates µ-opioid receptors within the GI
tract inhibiting intestinal peristalsis, increasing intestinal transit
time and promoting fluid reabsorption (Richardson and Dobish,
2007). The efficacy of DTO in treatment of CID has not been
reported, however, it is a commonly used anti-diarrheal drug
and may be considered as a second-line therapy for persistent
and uncomplicated diarrhea (Richardson and Dobish, 2007).
DTO contains 10 mg/ml of morphine and is one of the
most potent forms of orally administered morphine available
by prescription. DTO induces many side-effects including
euphoria, nausea, vomiting, painful/difficult urination, stomach
and abdominal pain, seizures and allergic reactions. Further,
DTO administration associates with psychological and physical
dependence, miosis, respiratory depression (Benson et al.,
2004a; Richardson and Dobish, 2007) and constipation, with
continued/prolonged opioid use linked to severe constipation
(Benyamin et al., 2008).
CHEMOTHERAPY-INDUCED
CONSTIPATION
Constipation is a frequent, and underestimated, complication
in patients with advanced cancer (Mancini and Bruera, 1998).
As constipation is a subjective sensation, there is difficulty
surrounding acceptance of a universal definition, although it is
broadly recognized clinically as a mixture of reduced frequency
of bowel action and increased stool consistency (Connolly and
Larkin, 2012). Constipation occurs in 50–87% of advanced cancer
patients (Abernethy et al., 2009). Constipation is the third most
common symptom in patients receiving cytotoxic chemotherapy
with an overall prevalence of 16%, with 5% classified as severe
and 11% classified as moderate (Yamagishi et al., 2009; Anthony,
2010).
The mechanisms underlying CIC are poorly defined with
minimal clinical studies existing. Distinguishing true CIC from
secondary constipation from drugs given to control other
chemotherapy or cancer-induced symptoms (such as anti-
emetics for nausea and vomiting and opioids for pain) is a major
issue hindering investigation (Gibson and Keefe, 2006). Given
the scarcity of literature concerning CIC it is hard to estimate
accurate incidence and severity among all chemotherapy-treated
cancer sufferers, but specific chemotherapeutic agents such as
thalidomide, cisplatin and vinca alkaloids such as vincristine,
vinblastine, and vinorelbine induce true CIC in up to 80–90%
of patients (Ghobrial and Rajkumar, 2003; Pujol et al., 2006;
Stojanovska et al., 2015).
Constipation is not deemed to be of clinical importance until
it causes physical risks or impairs quality of life. Constipation can
cause a number of significant symptoms. Severely constipated
patients experience abdominal distension usually accompanied
by severe abrupt episodes of abdominal pain (Falcón et al., 2016).
Furthermore, rectal tearing, hemorrhoids and rectal fissures
caused by passing hard, dry stool are frequent complications
of constipation (Leung et al., 2011). Untreated constipation
may progress to obstipation, severe persistent constipation,
which can have life threatening complications associated with
fecal impaction and bowel obstruction (Leung et al., 2011).
Fecal impaction, the presence of unpassable masses of stool,
and increases intraluminal pressure within the bowel can lead
to ischaemic necrosis of the mucosa, pain, bleeding, and
perforation. Fecal impaction is also well recognized as a factor
in urinary incontinence in the elderly (MacDonald et al., 1991).
Constipation can also cause confusion, increase retroperitoneal
or liver pain, trigger rapid onset nausea with or without
vomiting in the presence of intestinal blockage and lead to
inadequate absorption of oral drugs (Mancini and Bruera, 1998),
greatly affecting the tolerability and efficacy of chemotherapeutic
administration. There is accumulating evidence that self-reported
constipation and functional constipation lead to significant
impairment of quality of life, with the implication that this is a
serious condition in the majority of people aﬄicted (Talley, 2003;
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Dennison et al., 2005), however, little work has been undertaken
to elucidate prevalence and mechanisms.
Pathophysiology of
Chemotherapy-Induced Constipation
Normal bowel function requires the coordination of motility,
mucosal transport, and defecation reflexes (Mancini and Bruera,
1998). Broadly constipation can be classified into three categories:
normal-transit constipation, defecatory disorders and slow-
transit constipation (Lembo and Camilleri, 2003). Normal-
transit constipation is the most common form of constipation,
where frequency of colonic evacuation is normal, yet patients
believe they are constipated due to a perceived difficulty with
evacuation or the presence of hard stools. Symptoms of normal-
transit constipation include bloating and abdominal pain or
discomfort, as well as increased psychosocial distress (Ashraf
et al., 1996). Constipation resulting from defecatory disorders
is most commonly due to dysfunction of the pelvic floor or
anal sphincter. Defecatory disorders may result from prolonged
avoidance of the pain associated with the passage of a large, hard
stool or painful, anal fissure or hemorrhoid (Loening-Baucke,
1996). Structural abnormalities, such as rectal intussusception,
rectocele, obstructing sigmoidocele, and excessive perineal
descent, are less common causes of defecatory disorders (Lembo
and Camilleri, 2003). Slow-transit constipation is associated with
infrequent urge to defecate, bloating, and abdominal pain or
discomfort.
Though little clinical research has been undertaken to
elucidate the underlying pathology in CIC, it has been
hypothesized that CIC may result from effects of chemotherapy
on nerve endings in the gut (Ghobrial and Rajkumar, 2003).
The GI tract is innervated by the ENS together with fibers
from extrinsic sympathetic, parasympathetic (vagus nerve) and
sensory afferent neurons (Phillips and Powley, 2007). Both the
extrinsic and intrinsic innervation play an important role in
the motor activity of the GI tract. The internal circular smooth
muscle layer and the external longitudinal smooth muscle are
controlled by two main mechanisms: non-neural pacemaker
cells, interstitial cells of Cajal (ICCs), which generate myogenic
activity and enteric neurons which provide neurogenic supply.
Neuronal terminals are closely associated with ICCs which are
linked to smooth muscle cells via gap junctions. Within the ENS,
three main neuronal classes of myenteric neurons govern the
complex motor reflex pathways: sensory neurons, interneurons,
and motor neurons. The integration of inputs from these neurons
and ICCs to smooth muscle cells in the colon allows expression
of various motor patterns including phasic contractile activity
and tonic contractile activity which contribute to colonic motor
activity and the peristaltic reflex (Gwynne et al., 2004; Dinning
et al., 2009; Huizinga and Lammers, 2009; Kuizenga et al., 2015).
Subtle changes to the ENS, not evident in conventional
histological examination, have been suggested as a potential
underlying mechanism for abnormal colonic motor function
leading to constipation (Bassotti and Villanacci, 2011). For
instance, alterations in the number of myenteric neurons
expressing the excitatory neurotransmitter substance P, as well
as abnormalities in the inhibitory neurotransmitters, vasoactive
intestinal peptide and nitric oxide, and a reduction in the
number of ICCs (Cortesini et al., 1995; Tzavella et al., 1996;
He et al., 2000) have been observed in patients with slow-
transit constipation. However, the effects of chemotherapeutics
on ENS and GI dysfunction have been largely overlooked until
recently. A study investigating the effects of 5-fluorouracil-
induced dysmotility in mice uncovered myenteric neuronal
loss alongside delayed GI transit and inhibition of propagating
colonic contractions (McQuade et al., 2016). Similar results have
been demonstrated following oxaliplatin administration in mice,
and cisplatin administration in rats, where enteric neuronal loss
was associated with a reduction in colonic motor activity and
reduced GI transit time, respectively (Vera et al., 2011; Wafai
et al., 2013). Loss of enteric neurons following administration
of cisplatin and oxaliplatin has been correlated with an increase
in a population of the myenteric neurons expressing neuronal
nitric oxide synthase (Vera et al., 2011; Wafai et al., 2013) and
changes in glial cell populations (Robinson et al., 2016). These
studies emphasize the importance of enteric neuronal integrity
in GI function whilst suggesting neuroprotection as a potential
therapeutic pathway for the treatment of chemotherapy-induced
GI disorders.
Opioid-Induced Constipation
As previously mentioned, a major limitation in the estimation
and evaluation of true CIC is the onset of secondary
constipation, namely opioid-induced constipation produced by
opioid analgesia. Whilst opioid analgesics are the gold standard
in pain relief for cancer patients, adverse effects such as
opioid-induced bowel dysfunction (OIBD) and opioid-induced
constipation (OIC) severely compromise their therapeutic
potential (Gonzalez and Halm, 2016). Incidence of OIC ranges
from 50 to 87% in terminally ill cancer patients and is positively
associated with chronic opioid treatment (Abernethy et al.,
2009; Abramowitz et al., 2013). Opioid receptors are located
throughout the central and peripheral nervous system and are
involved in pain transmission (Camilleri, 2011). In the GI
tract, µ-receptors are widely distributed throughout the ileum,
stomach and proximal colon where they contribute to the control
of fluid and electrolyte transport as well as motility (McKay et al.,
1981; Fickel et al., 1997; Garg et al., 2016). Opioid analgesics
interfere with GI motility by delaying transit, stimulating non-
propulsive motility and altering GI segmentation and tone
through their effects on enteric neurons (De Schepper et al.,
2004; Wood and Galligan, 2004). These changes coupled with
activation of mucosal sensory receptors that trigger a reflex arc
facilitate excessive fluid reabsorption, resulting in OIC (Panchal
et al., 2007; Camilleri, 2011).
Whilst administration of laxatives remains the first-line
treatment option for OIC, this intervention alone is frequently
ineffective (Gatti and Sabato, 2012). Selective µ-opioid receptor
antagonists are emerging as a promising first line treatment for
OIC, in particular treatment with methylnaltrexone bromide
(methylnaltrexone) has been found to improve GI transit in
chronically ill patients and has been recommended for use
in cancer patients (Gatti and Sabato, 2012). Methylnaltrexone
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has demonstrated efficacy in improving opioid-induced delay
in the oral–caecal transit time and inducing laxation in both
healthy subjects and advanced illness patients (Culpepper-
Morgan et al., 1992; Thomas et al., 2005; Thomas et al.,
2008). Similarly, treatment with peripheral µ-opioid receptor
antagonist Alvimopan has been found to increase the frequency
of spontaneous bowel movements in non-cancer patients with
opioid induced bowel dysfunction (Webster et al., 2008).
Current Treatments for
Chemotherapy-Induced Constipation
The management of constipation can be divided into
general interventions and therapeutic measures. The general
interventions involve increasing physical exercise, fluid intake
and fiber consumption, availability of comfort, privacy and
convenience during defecation as well as elimination of medical
factors that may be contributing to constipation (Mancini and
Bruera, 1998). Therapeutic interventions for the management
of constipation, including CIC involve the administration of
both oral and/or rectal bulk-forming, emollient, osmotic/saline,
stimulant, and lubricant laxatives (Connolly and Larkin, 2012).
Laxative compounds may fall into one of several categories
depending on their mechanism of action.
Bulk-Forming Laxatives
Bulk-forming laxatives such as methylcellulose, psyllium, and
polycarbophil most closely mimic the physiologic mechanisms
involved in promoting GI evacuation. Available as natural or
semisynthetic hydrophilic polysaccharides, cellulose derivatives,
or polyacrylic resins, bulk forming laxatives work by either
dissolving or swelling in the intestines to form a viscous liquid
that provides mechanical distension. This facilitates the passage
of intestinal contents by stimulating peristalsis and reducing GI
transit time. Although typically recommended as initial therapy
for most forms of mild constipation (Kirschenbaum, 2001), bulk-
forming agents can take up to 72 h to exert their effects and
therefore are not ideal for the initial management of symptomatic
constipation in cancer patients (Avila, 2004; Connolly and Larkin,
2012). Bulk forming laxatives require the patients to drink extra
fluids as otherwise a viscous mass may form and aggravate a
partial bowel obstruction. In addition, significant allergy to these
substances has been reported, and their effectiveness in severe
constipation is doubtful (Klaschik et al., 2003). Though they are
considered safe, some patients’ experience suggests that they may
worsen symptoms, causing distension, bloating, and abdominal
pain (Costilla and Foxx-Orenstein, 2014).
Osmotic Laxatives
Osmotic laxatives such as lactulose, sorbitol, polyethylene
glycol compounds, and saline laxatives (magnesium hydroxide),
attract and retain fluid within GI tract (Twycross et al.,
2012). Osmotic laxatives include salts of poorly absorbable
cations (magnesium), anions (phosphate, sulfate) as well
as molecules that are not absorbed in the small bowel but
are metabolized in the colon (lactulose and sorbitol) and
metabolically inert compounds such as polyethylene glycol.
The presence of these molecules in the lumen results in
water retention to maintain normal osmolarity of the stool
(Costilla and Foxx-Orenstein, 2014). The laxative effect of
these agents depends on the extent to which they remain
in the lumen with the onset between 24 and 72 h (Xing
and Soffer, 2001). Adverse effects such as abdominal pain,
flatulence, cramping and distension can arise shortly after
ingestion, although side-effects may subside after several days
of treatment, higher lactulose doses can induce bloating and
colic (Ford and Suares, 2011; Costilla and Foxx-Orenstein,
2014). Excessive use of osmotic laxatives may result in
hypermagnesemia, hyperphosphatemia, hypercalcemia,
hypernatremia, hypokalemia, and hypoalbuminemia (Xing
and Soffer, 2001; Kurniawan and Simadibrata, 2011).
Emollient (Stool Softener) Laxatives
Emollient laxatives, also known as stool softeners, are
anionic surfactants increasing efficiency of intestinal fluids
and facilitating the mixing of aqueous and fatty substances
within the feces; this softens the feces allowing them to move
more easily through the GI tract (Avila, 2004). Stool softeners
are of little value when administered unaccompanied in the
treatment of long-term constipation as they do not stimulate
peristalsis and evacuation, but concurrent administration
with bulk-forming agents and dietary fiber provides beneficial
effect reducing straining (O’Mahony et al., 2001; Avila, 2004).
Increased fluid intake essential during treatment with emollient
laxatives to facilitate stool softening and so are not ideal for
chronic constipation in cancer patients. Docusate is the most
widely used emollient laxative produced as docusate calcium,
docusate sodium, and docusate potassium. The onset of action
is 1–2 days after administration but might be up to 5 days.
However, docusates have been found to enhance GI or hepatic
uptake of other drugs, increasing the risk of hepatotoxicity (Xing
and Soffer, 2001). There is also some evidence that docusates
cause significant neuronal loss in the myenteric plexus (Fox
et al., 1983) and cause structural changes in the gut mucosa of
humans (Xing and Soffer, 2001), but the clinical significance of
this remains unclear.
Stimulant Laxatives
Stimulant laxatives such as diphenylmethane derivatives
(phenolphthalein, sodium picosulfate, anthranoids (senna and
cascara), ricinoleic acid (castor oil), and surface-acting agents
directly stimulate myenteric neurons to increase peristalsis
resulting in reduced net absorption of water and electrolytes
from the intraluminal contents (Twycross et al., 2012). Stimulant
laxatives are more potent than bulk-forming and osmotic
laxatives and appear to be more effective than enemas (Dosh,
2002; Scarlett, 2004). They are amongst the most commonly
administered laxatives for opioid-induced constipation (Ruston
et al., 2013). Although short-term use is safe, overuse can cause
dehydration and long-term ingestion may result in laxative
dependence. This dependence also known as ‘laxative bowel’
is thought to result from damage to the myenteric plexus and
smooth muscles cells in the colon (Xing and Soffer, 2001;
Kurniawan and Simadibrata, 2011).
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Lubricant Laxatives
Lubricant laxatives emulsify themselves into the fecal mass,
coating the feces and rectum for easier passage whilst retarding
colonic water absorption to simultaneously soften stool (Avila,
2004). Liquid paraffin, also known as mineral oil, is the major
lubricant laxative in use although seed oils from croton and
arachis are also available (Xing and Soffer, 2001). These laxatives
can be administered orally or rectally and are useful for patients
who complain of excess straining, but long-term use is associated
with malabsorption of fat soluble vitamins and minerals, as well
as anal leakage (Costilla and Foxx-Orenstein, 2014). Lubricant
laxatives are not routinely recommended for long-term use due
to possible inflammatory conditions such as lipoid pneumonia
(Schiller, 1999).
Rectal Laxatives
Rectal laxatives such as bisacodyl (stimulant), sodium phosphate
(saline), glycerin (osmotic), and mineral oil (lubricant) (Avila,
2004) generally accepted not to be regularly used for CIC
treatment (Fallon and O’Neill, 1997), but may be necessary
alongside digital stimulation for treating fecal impaction or
constipation associated with neurogenic bowel dysfunction.
Rectal suppository of bisacodyl (stimulant) is most commonly
utilized when evacuation of soft stools is needed, while glycerin
suppositories are more appropriate when a hard stool needs to
be softened (Fallon and O’Neill, 1997). Acute severe constipation
might require an administration of rectal laxatives by enema,
however, rectal suppositories or enemas cannot be used in
patients with neutropenia and thrombocytopenia (O’Mahony
et al., 2001).
EMERGING AND POTENTIAL
TREATMENTS FOR CID AND CIC
As current therapies for CID and CIC have limited efficacy and
a plethora of adverse effects, a search for and use of novel anti-
diarrheal and laxative agents is essential to improve quality of
life and chemotherapeutic efficacy for cancer patients. Several
emerging and already existing therapies used for treatment
of other conditions such as diarrhea predominant irritable
bowel syndrome (IBS-D), constipation predominant irritable
bowel syndrome (IBS-C) and chronic idiopathic diarrhea and
constipation could be employed for the treatment of CID and
CIC.
Chloride Channel Inhibition and
Activation
Chloride is an essential ion in intestinal secretion and absorption.
Secretory diarrhea, such as that experienced in irinotecan-treated
patients, results from a combination of excessive secretion and
reduced absorption in the intestinal lumen (Thiagarajah and
Verkman, 2012). Excessive fluid secretion is driven by active
chloride secretion, followed by secondary movement of water and
sodium into the intestine. Although there is a lack of selective
potent inhibitors of voltage gated chloride channels, inhibition
of calcium-activated chloride channels throughout the intestines
successfully reduced secretion of chloride into the intestinal
lumen (Thiagarajah and Verkman, 2013; Thiagarajah et al., 2015).
In a mouse model of rotavirus-induced severe secretory diarrhea,
inhibition of calcium-activated chloride channels with a red
wine extract reduced intestinal fluid secretion, diminishing the
symptoms of diarrhea (Ko et al., 2014).
Conversely, chloride channel activation has been used in the
management of chronic idiopathic constipation and constipation
related to irritable bowel syndrome (IBS-C). Lubiprostone is a
bicyclic fatty acid derived from prostaglandin E1 that specifically
activates chloride channels in the intestine, whilst having no
effect on smooth muscle contraction (Jun, 2013). The underlying
mechanism of lubiprostone involves stimulation of electrogenic
chloride secretion though activation of chloride channel type-2
(Lacy and Levy, 2007) and cystic fibrosis transmembrane
conductance regulator chloride channels (Bijvelds et al., 2009)
in the apical membrane of intestinal epithelial cells. Activation
of these epithelial channels results in active secretion of
chloride into the intestinal lumen followed by a passive
secretion of electrolytes and water increasing the liquidity of
the luminal contents (June, 2013). Resulting luminal distension
from increased intestinal fluid content promotes GI motility and
increases intestinal and colonic transit. In healthy volunteers,
daily lubiprostone delays gastric emptying, increases fasting
gastric volume, reduces maximum tolerated gastric volume, and
accelerates small bowel and colon transit (Camilleri et al., 2006).
In randomized trials involving patients with IBS-C, lubiprostone
twice daily reduced abdominal pain and increased complete
spontaneous bowel movement and improved stool consistency,
straining, and bloating (Schey and Rao, 2011). Currently, oral
lubiprostone is approved for IBS-C at 8 µg twice daily and CIC at
doses of 24 µg twice daily, but approval for CIC is limited to only
women who have not responded to laxatives (Davis and Gamier,
2015). At present there are no studies investigating the efficacy of
lubiprostone for CID.
Cannabinoid Receptor Inhibition and
Activation
Cannabinoids mediate their effects via binding to two main
G-protein coupled receptors, CB1 and CB2, widely expressed in
the GI tract (Abalo et al., 2012). Although the activity of the
endocannabinoid system varies between species and different
regions of the GI tract within the same species, activation of CB1
receptors coupled to cholinergic motor neurons has been found
to inhibit excitatory neuromuscular transmission in human
colonic circular muscle (Hinds et al., 2006) and inhibit colonic
propulsion in mice and rat (Pinto et al., 2002; Abalo et al., 2015).
In recent human trials, dronabinol, a non-selective cannabinoid
receptor agonist, was found to inhibit colonic motility in both
healthy subjects (Esfandyari et al., 2006, 2007) and patients with
IBS-related diarrhea (IBS-D) (Wong et al., 2011). Conversely,
a CB1 receptor inverse agonist, taranabant, has been shown to
improve symptoms related to slow GI motility and abdominal
pain when administered in vivo in mice (Fichna et al., 2013).
Taranabant increased the number of bowel movements after
systemic and oral administration and significantly increased fecal
pellet output in mice with constipation induced by ipratropium
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(Fichna et al., 2013). It has been demonstrated that a low dose
of a non-selective cannabinoid agonist WIN55,212-2 reduced the
severity of 5-fluorouracil-induced diarrhea in rats (Abalo et al.,
2016).
Guanylate Cyclase C Activation
Guanylate cyclase C is the principal receptor for heat-
stable enterotoxins and plays a major role in E. coli-
induced secretory diarrhea (Camilleri, 2010). Enterotoxins and
endogenous peptides bind to guanylate cyclase C and stimulate
the production of intracellular cyclic guanosine monophosphate
(cGMP). Increased levels of cGMP activate the secretion
of chloride ions through the cystic fibrosis transmembrane
conductance regulator. Linaclotide is a minimally absorbed 14-
aminoacid peptide that selectively stimulates intestinal epithelial
cell guanylate cyclase C receptors, resulting in increased
intracellular and extracellular cGMP leading to accelerated stool
transit and laxation (Harris and Crowell, 2007). In phase II and
III placebo-controlled studies in chronically constipated and IBS-
C patients, linaclotide was found to accelerate colonic transit
and improve abdominal pain and symptoms of constipation
(Andresen et al., 2007; Johnston et al., 2009, 2010; Lembo et al.,
2010). Linaclotide is particularly interesting in that it is both
a laxative and analgesic, reducing visceral hypersensitivity with
very few drug interactions, it is presently licensed for chronic
idiopathic constipation and IBS-C in the USA (Davis and Gamier,
2015), but no trials on CIC have been reported to date.
Probiotics, Antibiotics, and
β-glucuronidase Inhibitors
With the recognition that intestinal microbiota play key roles in
the pathophysiology of mucositis and development of CID/CIC,
both antibiotics and probiotics have emerged as promising
therapeutic options. Administration of probiotics have been
shown to prevent CID in both 5-fluorouracil and irinotecan-
treated animals (Bültzingslöwen et al., 2003; Bowen et al.,
2007). Similarly, a combination of Lactobacillus rhamnosus
and fiber has been found to reduce the severity of grade
3/4 5-fluorouracil/leucovorin-induced diarrhea by 15% in a
randomized study of patients treated for colorectal cancer
(Österlund et al., 2007). Administration of oral antibiotics, such
as fluoroquinolone, has also been recommended for aggressive
treatment of CID (Benson et al., 2004a; Maroun et al., 2007).
The selective inhibition of bacterial β-glucuronidase has
recently been shown to alleviate drug-induced GI toxicity in
mice (Wallace et al., 2015). A low-potency β-glucuronidase
inhibitor showed promise in reducing the GI toxicity associated
with irinotecan in rats (Fittkau et al., 2004). Similarly, oral
administration of potent bacterial β-glucuronidase inhibitors
has been found to reduce the severity of irinotecan-induced
toxicity (Wallace et al., 2010). In clinical trials, Kampo
medicine Hangeshashinto (TJ-14) which contains baicalin, a
β-glucuronidase inhibitor, has been found to successfully reduce
both the incidence and duration of chemotherapy-induced
oral mucositis in colorectal cancer patients when compared
to placebo patients (Matsuda et al., 2015). In non-small-cell
lung cancer patients TJ-14 alleviated irinotecan-induced diarrhea
(Mori et al., 2003). Compared with control patients, the TJ-
14-treated patients showed a significant improvement in both
diarrhea grade, as well as a reduced frequency of grade 3 and 4
diarrhea (Mori et al., 2003).
CONCLUSION
Chemotherapy-induced diarrhea and CIC are amongst the
most common chemotherapy-induced GI toxicities, heavily
contributing to treatment delays, dose reductions and in
some cases cessation of anti-cancer treatment, greatly effecting
management and clinical outcomes. Current treatments for
CID and CIC are limited and come with a profuse amount
of concomitant symptoms; however, novel therapies present a
promising avenue of treatment for CID and CIC. Identification
of potential targets and the development of novel treatments
alleviating chemotherapy-induced toxicity are essential to
improve clinical outcomes and quality of life amongst cancer
sufferers.
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